Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort.
Katharina MitzlaffMartha M KirsteinChristian MüllerMarino VeneritoAlexander OlkusMichael T DillArndt WeinmannLorenz KocheiseAlina BuschKornelius SchulzeGabriel AlloDirk-Thomas WaldschmidtMaryam BarschBertram BengschMichael QuanteMaria A Gonzalez-CarmonaVera HimmelsbachFabian FinkelmeierRoman KloecknerPeter SchirmacherJens-Uwe MarquardtCarolin CzaudernaPublished in: United European gastroenterology journal (2024)
Immuno-chemotherapy in patients with BTC was feasible, effective and safe in a real-life scenario. Our results were comparable to the phase 3 clinical trial results (TOPAZ-1). Reduced efficacy was noted in patients with GB-CA and/or a reduced performance status that warrants further investigation.